WebFDA label information for this drug is available at DailyMed. Use in Cancer. Daratumumab is approved to be used alone or with other drugs to treat: Multiple myeloma. ... With pomalidomide and dexamethasone in patients who have received at least two therapies that included lenalidomide and a proteasome inhibitor. WebPomalyst (pomalidomide) has black box warnings for embryo-fetal toxicity and venous and arterial thromboembolism. Pomalyst, as a thalidomide analogue, is contraindicated in …
Join the My Momentum Support Program - POMALYST® (pomalidomide)
WebPOMALYST is a prescription medicine used to treat adults with: Multiple myeloma, taken along with the medicine dexamethasone, in patients who have previously received at least 2 medicines to treat multiple myeloma, including a proteasome inhibitor and lenalidomide, and whose disease has become worse during treatment or within 60 days of finishing the last … WebSep 15, 2024 · DailyMed is migrating to cloud services on September 14, 2024 . The look and feel of DailyMed will not change in the cloud. Aside from improved performance, users should not expect any changes to their DailyMed experience following the move to the cloud. As previously announced, DailyMed will be switching from static IP addresses to … solve f x 1/5 x
HIGHLIGHTS OF PRESCRIBING INFORMATION
WebMar 27, 2024 · Pomalyst comes in four strengths: 1 milligram (mg), 2 mg, 3 mg, and 4 mg. Typical dosages. The following information describes dosages that are commonly used or recommended. WebFeb 16, 2024 · Dosage for multiple myeloma. For multiple myeloma, the Pomalyst dosage is 4 mg taken once daily for the first 21 days of your 28-day treatment cycle. Then for the final 7 days of every treatment ... WebPomalidomide is a yellow solid powder. It has limited to low solubility into organic solvents and it has low solubility in all pH solutions (about 0.01 mg/mL). Pomalidomide has a … solve gmbh buchs